Pathway Genomics Announces Definitive Settlement With United States

Pathway Genomics Announces Definitive Settlement With United States

SAN DIEGO, Dec. 30, 2015 /PRNewswire/ -- Pathway Genomics has reached a settlement with the United States Department of Justice. Pathway admits no wrongdoing as part of the settlement and is neither an admission of liability or wrongdoing by the Company, nor a concession by the United States that its claims are not well founded.

Pathway has fully cooperated with the inquiry and was not required to enter into a corporate integrity agreement. We now consider this matter closed. By resolving this issue we can stay focused on our growing business and avoid the time and expense of a potentially lengthy litigation process. 

Although Pathway may debate some of the merits of the DOJ's allegations, we recognize and respect the government's responsibility to regulate industry practices. We continue to offer our full array of advanced genetic tests that empowers physicians and patients with accurate and actionable information that allows them to live better and healthier lives.

Media contact: Lesli Gallagher, [email protected], 520-661-6317


Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.